EISAI SELECTS MEDIDATA'S CLINICAL DATA STUDIO TO ENHANCE AND MODERNIZE CLINICAL TRIAL EFFICIENCY AND PATIENT EXPERIENCE

AI-enhanced solution will help Eisai accelerate data review and reconciliation by 80%

NEW YORK, July 29 (Bernama-BUSINESS WIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”

Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.

“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

About Eisai Inc.

Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn. 

http://mrem.bernama.com/viewsm.php?idm=49070

VOTIRO HIGHLIGHTS CONTINUOUS MOMENTUM IN THE ASIA-PACIFIC

Company unveils key executive appointments, industry partnerships, and market growth within the region

SINGAPORE, July 26 (Bernama-BUSINESS WIRE) --Votiro, innovator in Zero Trust Data Detection and Response and trusted to deliver safe and compliant content to industry leaders across the globe, announces significant growth and advancements in Asia-Pacific (APAC) and Japan. The company also shares its plans to advance product functionality within the region in the second half of the year, expanding its Content Disarm and Reconstruction (CDR) engine with a real-time data security pillar via Zero Trust Data Detection & Response (DDR).

To lead expansion in the large growth market, the company has appointed John Ong as Regional VP of Sales, APAC, Japan, and Middle East. Ong joins Votiro with more than two decades of experience in the cybersecurity industry at companies including Panorays, AlgoSec, and Check Point Software Technologies. With a deep understanding of direct and indirect business models specific to the dynamic APAC market, Ong is well-positioned to drive regional growth and serve existing customers and partners.

“We are excited to welcome John to the Votiro team. John brings a wealth of expertise and understanding of the complexities of the digital security business and channel-focused growth. He is the ideal leader for continuing to build and lead Votiro’s momentum in the region,” said Ravi Srinivasan, CEO of Votiro. “We are committed to helping our APAC, Japan, and Middle East customers and partners accelerate cybersecurity strategies and maintain an always-safe and -compliant posture. We look forward to working with John and his team to introduce our new real-time data security solutions and further product functionalities with technology partners.”

In recent months, Votiro has implemented key technology integrations with industry partners, including Microsoft SharePoint, Zscaler ZIA, and Palo Alto Networks Prisma platforms. The company has also strengthened existing integrations with partners such as Menlo Security, SumoLogic, industry-leading Enterprise Security Browsers, Microsoft Teams, and Microsoft OneDrive. With all these open, API-based integrations, Votiro can help more enterprise users eliminate the risk of file-borne data privacy exposure and proactively prevent unknown malware, and other evasive malicious attempts to gain initial access in the first place. 

http://mrem.bernama.com/viewsm.php?idm=49057

EISAI SELECTS MEDIDATA'S CLINICAL DATA STUDIO TO ENHANCE AND MODERNIZE CLINICAL TRIAL EFFICIENCY AND PATIENT EXPERIENCE

AI-enhanced solution will help Eisai accelerate data review and reconciliation by 80%

NEW YORK, July 25 (Bernama-BUSINESS WIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience.

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”

Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.

“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.”

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com.

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.

About Eisai Inc.

Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn. 

http://mrem.bernama.com/viewsm.php?idm=49055

FAST COMPANY MAGAZINE AWARDS XENCO MEDICAL WITH 2024 INNOVATION BY DESIGN AWARD FOR THE TRABECULEX CONTINUUM

SAN DIEGO, July 25 (Bernama-BUSINESS WIRE) -- Fast Company Magazine has awarded pioneering life sciences company Xenco Medical with its prestigious 2024 Innovation by Design Award for its groundbreaking TrabeculeX Continuum, the first convergent technology bridging regenerative medicine and digital health. Unveiled by Xenco Medical at CES 2024, the heralded platform’s unification of biomaterial implantation and remote therapeutic monitoring has signified an important advancement in the extent to which surgeons can maintain a continuous link with patients from the intraoperative phase throughout the entire course of recovery. The distinguished award marks the second time in two consecutive years that Xenco Medical has been recognized by Fast Company Magazine for its breakthrough innovations. Last year, Xenco Medical was named one of the World’s Most Innovative Companies by the esteemed publication.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20240724363293/en/

 

“We are immensely honored to receive Fast Company’s 2024 Innovation by Design Award for the TrabeculeX Continuum and deeply grateful for their recognition of our technology’s capacity to upend the siloed nature of surgical care. Devoted to the longitudinal recovery of our patients, we look forward to the continued impact of the TrabeculeX Continuum as a seamless link from implantation to full mobility,” said Xenco Medical Founder and CEO Jason Haider.

According to Fast Company Magazine, the Innovation by Design Award “is one of the most sought-after design awards in the industry.” “This year’s honorees show how essential creativity is to the process of innovation,” said Brendan Vaughan, editor-in-chief of Fast Company. “It’s inspiring to see how some of the best minds across industries are using design to shape our world for the better.” Harmonizing the journey from biomaterial implantation to physical rehabilitation, Xenco Medical’s TrabeculeX Continuum enables surgeons who’ve used a TrabeculeX Bioactive Matrix strip in their patient to prescribe and remotely monitor patient-specific physical rehabilitation plans while engaging in asynchronous video and text messaging through the TrabeculeX Recovery App. Intricately designed to conduct three-dimensional bone-formation, the TrabeculeX Bioactive Matrix’s novel architecture begins at the sub-micron scale and spans to the entire lattice itself.

Harnessing the hydroxycarbonate apatite-forming capabilities of bioglass in every TrabeculeX Bioactive Matrix, the regenerative biomaterial included in the TrabeculeX Continuum features a complex surface topography chemically engineered for robust bone regeneration. Driven by a mission to deliver value-based care through surgical innovation, Xenco Medical’s breakthrough technologies have been uniquely centered on addressing the entire spectrum of a surgical patient’s journey. The Innovation by Design Awards will be published in the Summer 2024 issue of Fast Company Magazine, and the honorees will be celebrated in New York City at the Innovation by Design Awards Reception on the evening of September 16th. 

http://mrem.bernama.com/viewsm.php?idm=49051

KIOXIA RECOGNISED FOR GROUNDBREAKING BICS FLASH 3D FLASH MEMORY TECHNOLOGY

KUALA LUMPUR, July 25 (Bernama) -- Kioxia Corporation, the inventor of NAND flash memory, was honoured by FMS: the Future of Memory and Storage with 2024 Lifetime Achievement Award for 3D NAND flash invention.

This breakthrough technology has become fundamental to a wide range of computing applications, including advanced smartphones, personal computers, solid state drives (SSDs), data centres, artificial intelligence, and industrial.

“Our technology has created a new paradigm in the industry, enabling flash memory to vastly increase storage density per cell, die and package.

“I am excited to see our achievements recognised and look forward to witnessing their continued influence in the years to come," said its vice president and technology executive for Memory Division, Atsushi Inoue in a statement.

The Kioxia engineering team, consisting of Hideaki Aochi, Ryota Katsumata, Masaru Kito, Masaru Kido, and Hiroyasu Tanaka, will accept this prestigious award for its pioneering work in developing and commercialising 3D flash memory.

Kioxia presented the concept of BiCS FLASH 3D flash memory technology at the VLSI Symposium in 2007. After announcing the prototype, Kioxia continued development to optimise the technology for mass production, eventually introducing the world’s first 256 gigabit, 48-layer 3D flash memory in 2015.

With a 3D stacked structure that boosts capacity and performance, BiCS FLASH 3D flash memory has been a transformational force in the storage industry.

The technology has enabled higher density storage solutions while maintaining reliability and efficiency, significantly enhancing the capabilities of data centres, consumer electronics, and mobile devices, setting a new standard for flash memory technology.

By leveraging vertical stacking, Kioxia’s BiCS FLASH technology addressed the limitations of planar NAND flash, paving the way for future developments in memory storage solutions, and reinforcing Kioxia Corporation as an industry leader.

-- BERNAMA

POLICYMAKERS URGED TO EMBRACE SELF-CARE IN ADDRESSING GLOBAL HEALTH ISSUES

KUALA LUMPUR, July 24 (Bernama) -- Policymakers and health leaders worldwide are urged to embrace self-care as an essential component of healthcare, by ensuring it is fully integrated into national health systems and policies, as part of this year’s International Self-Care Day.

The Global Self-Care Federation (GSCF) is urging members and campaigners to rally behind the #SelfCareIs movement, which aims to educate global audiences about the critical link between self-care and healthcare.

This initiative also encourages engagement with local policymakers and healthcare providers to call on them to put in place plans for the urgent integration of self-care into the healthcare delivery continuum.

“Our ‘Self-care is healthcare’ campaign is all about fuelling the movement for self-care to be recognised as an integral part of healthcare. It aims to drive greater awareness and recognition of the potential of self-care to people and policymakers across the world.

“At GSCF, we firmly believe that everyone benefits when there is a greater choice of healthcare options and more accessible entries to care,” said its Director General, Judy Stenmark in a statement.

As health systems worldwide continue to face a range of challenges from increased demand on services, to inequity in access to healthcare, evidence shows that self-care can avert an estimated 3.9 million premature deaths each year, through physical activity alone.

In addition, self-care is able to save billions of dollar each year for global healthcare systems and, therefore, national economies; improve the autonomy and agency of disadvantaged groups, including women and girls, in managing their own health; as well as provide a legitimate tool in the pursuit of universal health coverage. 

First recognised by the World Health Organization (WHO) in 1983, the concept of self-care describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare.

Representing associations and manufacturers in the self-care industry, promoting sustainable and better global health outcomes for all, GSCF is the go-to source of information for the self-care industry.

-- BERNAMA 

NIPPON KINZOKU'S COLD PROFILE ROLLED PRODUCTS ARE NAMED "FINE PROFILE" TO STRENGTHEN SALES EXPANSION

Contributing to the Realization of Carbon Neutrality Through Resource- and Energy-Saving Processing Technology

TOKYO, July 23 (Bernama-BUSINESS WIRE) -- NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) announces that it has named and registered the trademark "Fine Profile" for its cold profile rolled products, which can be used for various metals from ferrous to nonferrous, by combining its proprietary cold rolling technology and specialized equipment.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20240723992481/en/

 

Fine Profile is our original new product that contributes to customers' manufacturing cost reduction and yield improvement as an alternative to various machining processes such as cutting and grinding, and we aim to expand sales of this product in the future.

Features

1. Cost reduction of metal processing, resource saving, energy saving
   Use of a deformed cross-sectional shape contributes to reduce machining processes and waste.
2. Stabilization of quality
   Continuous rolling from coil provides stable supply of high quality products.
3. Roll forming on metal surfaces
   By rolling the uneven pattern on the roll surface, it is possible to process various designs and functions such as unique designs, oil grooves, gloss prevention, identification grooves, etc.
4. Various delivery forms
   We can deliver products in a variety of forms, such as record rolls, oscillate rolls, fixed-length products, and secondary processing, etc. according to customer needs.
5. Shorter development period
   Roll design using CAE analysis contributes to reduction of customers' development cost and time.

Metal types

Nonferrous metals: oxygen-free copper, copper alloys, aluminum alloys, pure titanium, titanium alloys, pure nickel, magnesium alloys, etc.
Stainless steel: SUS304 (L), SUS316 (L), SUS430, SUS420J2, SUS440C, etc.
Carbon steel: SS400, SPCD, SPCC, SPHC, SECC, etc.
Special steel: SCM415, SUJ2, S10C, S45C, S65C, SAE1070, SK75, SK95, SKS81, 1LSSP, etc.

* Please inquire separately for specifications other than those listed above.

Application examples

Fine Profile is developed and manufactured by our rolling technologies and co-creation with our customers that require stable quality and reliability in various applications.

1. Automotive applications (Automotive drive parts, Bearing components, Vane pump parts, Engine parts, etc.)
2. Electrical and electronic parts applications (Connector parts, Secondary battery terminals, Heat spreaders, Bus bars, etc.)
3. Building material applications (Grating components, Braille studs, Screen components, Special fasteners, etc.)

About NIPPON KINZOKU Group

Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/ 

http://mrem.bernama.com/viewsm.php?idm=49036